Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1

BH3-only proteins and their roles in programmed cell death

(2009) M Giam et al.   ONCOGENE

Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors

(2008) K. F. Whitecross et al.   BLOOD

MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells

(2008) Sai-Wen Tang et al.   CANCER LETTERS

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

ABT-737, proving to be a great tool even before it is proven in the clinic

(2008) D L Vaux   CELL DEATH AND DIFFERENTIATION

Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?

(2008) V Labi et al.   CELL DEATH AND DIFFERENTIATION

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

(2008) Mark S. Cragg et al.   JOURNAL OF CLINICAL INVESTIGATION

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY